Search - tctmd.com

Displaying 1 - 20 of 87

Sort: Relevancy | Date

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

AI-Supported Coaching Shows Promise for Improving Glycemic Control

L.A. McKeown

August 25, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Caitlin E. Cox

February 26, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

Todd Neale

October 01, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

Semaglutide May Ease Tobacco Use, Study Suggests

Todd Neale

August 01, 2024

News Daily News

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

Yael L. Maxwell

July 15, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

Advertisement

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

AI-Supported Coaching Shows Promise for Improving Glycemic Control

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

January 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Semaglutide May Ease Tobacco Use, Study Suggests

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

TCTMD’s Top 10 Most Popular Stories for May 2024

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content